CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 1,772	$ 1,643
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	4,120	3,592
Deferred income taxes	(714)	(105)
Provision for allowances	59	383
Share-based compensation	439	361
Change in fair value of interest rate swaps	(57)	(60)
Decommissioning retirement liability	32	29
Loss on sale of equipment	3	2
Gain on sale of marketable securities	(1)
Changes in assets and liabilities:
Accounts receivable	(546)	(1,495)
Inventories	(456)	(1,550)
Prepaid expenses and other current assets	(147)	(53)
Trade accounts payable	195	96
Accrued salaries, wages and payroll taxes	(451)	341
Income taxes payable	461	462
Other current liabilities	(60)	(195)
Other	286	(56)
Net cash provided by operating activities	4,935	3,395
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases and construction of property and equipment	(982)	(1,304)
Cash paid for acquisition of Core Oncology customer base	(4,755)
Proceeds from sale of property and equipment		5
Purchases of marketable securities	(3,271)	(7,743)
Maturities of marketable securities	4,079	5,955
Proceeds from sales of marketable securities	189
Net cash used by investing activities	(4,740)	(3,087)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of borrowings	(1,667)	(1,667)
Employee stock purchase plan	36	27
Retirement of common stock		(14)
Net cash used by financing activities	(1,631)	(1,654)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,436)	(1,346)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	29,553	29,674
CASH AND CASH EQUIVALENTS AT END OF PERIOD	28,117	28,328
SUPPLEMENTARY CASH FLOW DISCLOSURE:
Interest paid	361	417
Income taxes paid	1,128	613
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Assets acquired from the Core transaction	4,582
Liability for property and equipment acquired	$ 36	$ 63